Search Results

SGC0946 50 mg  | 99.82%

TargetMol

SGC0946 is a highly effective and specific DOT1L methyltransferase inhibitor (IC50: 0.3 nM); selectively kill mixed lineage leukemia cells.

More Information Supplier Page

SGC0946 5 mg  | 99.82%

TargetMol

SGC0946 is a highly effective and specific DOT1L methyltransferase inhibitor (IC50: 0.3 nM); selectively kill mixed lineage leukemia cells.

More Information Supplier Page

Obatoclax Mesylate 5 mg  | Purity Not Available

TargetMol

Obatoclax is a Bcl-2 antagonist (Ki: 0.22 μM) and can induce apoptosis with up-regulation of Bim, induced cytochrome c release, and activation of caspase-3.

More Information Supplier Page

Obatoclax Mesylate 50 mg  | Purity Not Available

TargetMol

Obatoclax is a Bcl-2 antagonist (Ki: 0.22 μM) and can induce apoptosis with up-regulation of Bim, induced cytochrome c release, and activation of caspase-3.

More Information Supplier Page

Obatoclax Mesylate 10 mg  | Purity Not Available

TargetMol

Obatoclax is a Bcl-2 antagonist (Ki: 0.22 μM) and can induce apoptosis with up-regulation of Bim, induced cytochrome c release, and activation of caspase-3.

More Information Supplier Page

Enzalutamide 50 mg  | 100.00%

TargetMol

Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells).

More Information Supplier Page

Enzalutamide 25 mg  | 100.00%

TargetMol

Enzalutamide (MDV 3100) is a non-steroidal androgen receptor (AR) antagonist (IC50: 36 nM in LNCaP prostate cells).

More Information Supplier Page

GSK-J1 10 mg  | 99.67%

TargetMol

GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.

More Information Supplier Page

GSK-J1 25 mg  | 99.67%

TargetMol

GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.

More Information Supplier Page

GSK-J1 50 mg  | 99.67%

TargetMol

GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.

More Information Supplier Page